92 related articles for article (PubMed ID: 31710433)
1. A Novel Approach of Urinary Monohydroxyphenyl Metabolites Assay in Cancer Screening.
Gan C; Yao LQ; Su N; Zhu JH; Li F; Li WT; Wang YY; Shi YX; Yu HT
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710433
[TBL] [Abstract][Full Text] [Related]
2. Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins.
Khadjavi A; Mannu F; Destefanis P; Sacerdote C; Battaglia A; Allasia M; Fontana D; Frea B; Polidoro S; Fiorito G; Matullo G; Pantaleo A; Notarpietro A; Prato M; Castagno F; Vineis P; Gontero P; Giribaldi G; Turrini F
Br J Cancer; 2015 Jul; 113(3):469-75. PubMed ID: 26125446
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
[TBL] [Abstract][Full Text] [Related]
4. Cancer detection by native fluorescence of urine.
Masilamani V; Vijmasi T; Al Salhi M; Govindaraj K; Vijaya-Raghavan AP; Antonisamy B
J Biomed Opt; 2010; 15(5):057003. PubMed ID: 21054119
[TBL] [Abstract][Full Text] [Related]
5. Update on urine as a biomarker in cancer: a necessary review of an old story.
Zhang W; Zhang XJ; Chao SY; Chen SJ; Zhang ZJ; Zhao J; Lv YN; Yao JJ; Bai YY
Expert Rev Mol Diagn; 2020 May; 20(5):477-488. PubMed ID: 32212972
[No Abstract] [Full Text] [Related]
6. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
7. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
8. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
[TBL] [Abstract][Full Text] [Related]
9. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
10. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
[TBL] [Abstract][Full Text] [Related]
11. Urinary protein biomarkers in the early detection of lung cancer.
Nolen BM; Lomakin A; Marrangoni A; Velikokhatnaya L; Prosser D; Lokshin AE
Cancer Prev Res (Phila); 2015 Feb; 8(2):111-9. PubMed ID: 25416410
[TBL] [Abstract][Full Text] [Related]
12. Cancer metabolomic markers in urine: evidence, techniques and recommendations.
Dinges SS; Hohm A; Vandergrift LA; Nowak J; Habbel P; Kaltashov IA; Cheng LL
Nat Rev Urol; 2019 Jun; 16(6):339-362. PubMed ID: 31092915
[TBL] [Abstract][Full Text] [Related]
13. Relevance of urine telomerase in the diagnosis of bladder cancer.
Sanchini MA; Gunelli R; Nanni O; Bravaccini S; Fabbri C; Sermasi A; Bercovich E; Ravaioli A; Amadori D; Calistri D
JAMA; 2005 Oct; 294(16):2052-6. PubMed ID: 16249419
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
15. The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.
Narayan VM; Adejoro O; Schwartz I; Ziegelmann M; Elliott S; Konety BR
J Urol; 2018 Jan; 199(1):74-80. PubMed ID: 28859894
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of an assay for urinary tissue factor activity.
Lwaleed BA; Chisholm M; Francis JL
J Clin Pathol; 1999 Mar; 52(3):219-24. PubMed ID: 10450183
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
[TBL] [Abstract][Full Text] [Related]
19. A highly accurate inclusive cancer screening test using Caenorhabditis elegans scent detection.
Hirotsu T; Sonoda H; Uozumi T; Shinden Y; Mimori K; Maehara Y; Ueda N; Hamakawa M
PLoS One; 2015; 10(3):e0118699. PubMed ID: 25760772
[TBL] [Abstract][Full Text] [Related]
20. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
